Literature DB >> 7698588

Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities.

P Podevin1, Y Calmus, M T Bonnefis, C Veyrunes, C Chereau, R Poupon.   

Abstract

BACKGROUND/AIMS: The mechanisms involved in resistance to interferon alfa in patients with chronic hepatitis C are unclear. Both cirrhosis and cholestasis have been shown to be predictive of resistance. The aim of this study was to evaluate the influence of cholestasis and bile acids on 2',5'-oligoadenylate synthetase and natural killer activities, which are both involved in the antiviral activity of interferon.
METHODS: 2',5'-Oligoadenylate synthetase activity was evaluated in spleen, liver, and isolated hepatocytes from bile duct-ligated rats, and the effect of bile acids in vitro on interferon-induced 2',5'-oligoadenylate synthetase and natural killer activities was examined in fresh mononuclear cells from healthy subjects.
RESULTS: Cholestasis had a time-dependent inhibitory effect on 2',5'-oligoadenylate synthetase activity in liver, spleen, and isolated hepatocytes from cholestatic rats (-70%, 86%, and 70% relative to baseline, respectively). In vitro, endogenous bile acids had a concentration-dependent inhibitory effect on interferon-induced 2',5'-oligoadenylate synthetase and natural killer activities, which was related to their structure. This inhibitory effect correlated with the surface activity index.
CONCLUSIONS: Cholestasis and bile acids diminish the biological activity of interferon and natural killer activity. The results suggest a decrease in the antiviral defenses in cholestatic conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698588     DOI: 10.1016/0016-5085(95)90219-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

2.  Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature.

Authors:  K S Kumar; M H Saboorian; W M Lee
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

3.  Immunosuppressive effect of chenodeoxycholic acid on natural killer cell activity in patients with biliary atresia and hepatitis C virus-related liver cirrhosis.

Authors:  Masaru Hirata; Yasushi Harihara; Yoshiaki Kita; Shoichi Saito; Motoko Nishimuraj; Hiroyuki Yoshino; Keiji Sano; Mitsuhiro Ito; Koji Kusaka; Hideo Kawarasaki; Kohei Hashizume; Masatoshi Makuuchi
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

4.  Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection.

Authors:  Tetsuro Sekiguchi; Takeaki Nagamine; Hitoshi Takagi; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

5.  Bile acids promote the expression of hepatitis C virus in replicon-harboring cells.

Authors:  Kyeong-Ok Chang; David W George
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

6.  Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function.

Authors:  Zhen Xun; Jinpiao Lin; Qingqing Yu; Can Liu; Jinlan Huang; Hongyan Shang; Jianhui Guo; Yuchen Ye; Wennan Wu; Yongbin Zeng; Songhang Wu; Siyi Xu; Tianbin Chen; Jing Chen; Qishui Ou
Journal:  Cell Mol Immunol       Date:  2021-01-11       Impact factor: 11.530

Review 7.  The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Authors:  M R Player; P F Torrence
Journal:  Pharmacol Ther       Date:  1998-05       Impact factor: 12.310

Review 8.  Role of bile acids in inflammatory liver diseases.

Authors:  Ioannis Evangelakos; Joerg Heeren; Esther Verkade; Folkert Kuipers
Journal:  Semin Immunopathol       Date:  2021-07-08       Impact factor: 9.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.